Literature DB >> 19890890

Wnts, bone and cancer.

David M Thomas1.   

Abstract

The Wnt pathway plays vital roles in bone and in cancer. In this issue of The Journal of Pathology, Cai and colleagues report results that suggest that the Wnt pathway is inactivated in bone cancers, a finding that could have significant implications for the development of Wnt agonists as bone anabolic agents. While these findings are at odds with the prevailing view that the Wnt pathway is oncogenic in all systems studied to date, they remind us how complex and still poorly understood this important signalling pathway remains. At the very least, these findings should provoke debate and stimulate further research into the role of Wnt signalling in osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19890890     DOI: 10.1002/path.2635

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Influence of β-catenin small interfering RNA on human osteosarcoma cells.

Authors:  Fan Zhang; Anmin Chen; Jianfeng Chen; Tian Yu; Fengjing Guo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

2.  Identification of Differentially Expressed Genes under the Regulation of Transcription Factors in Osteosarcoma.

Authors:  Yang Liu; Jianzhong Guan; Xiaotian Chen
Journal:  Pathol Oncol Res       Date:  2018-11-08       Impact factor: 3.201

Review 3.  A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers.

Authors:  Olivia M Lucero; David W Dawson; Randall T Moon; Andy J Chien
Journal:  Curr Oncol Rep       Date:  2010-09       Impact factor: 5.075

4.  Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β-catenin, p53, caspase 3) in canine appendicular osteosarcoma.

Authors:  Laura Bongiovanni; Francesca Mazzocchetti; Daniela Malatesta; Mariarita Romanucci; Andrea Ciccarelli; Paolo Buracco; Raffaella De Maria; Chiara Palmieri; Marina Martano; Emanuela Morello; Lorella Maniscalco; Leonardo Della Salda
Journal:  BMC Vet Res       Date:  2012-06-11       Impact factor: 2.741

5.  Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival.

Authors:  Yao Lu; Guo-Feng Guan; Jie Chen; Bin Hu; Cong Sun; Qiong Ma; Yan-Hua Wen; Xiu-Chun Qiu; Yong Zhou
Journal:  Oncol Lett       Date:  2015-07-24       Impact factor: 2.967

6.  Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin.

Authors:  Shingo Shimozaki; Norio Yamamoto; Takahiro Domoto; Hideji Nishida; Katsuhiro Hayashi; Hiroaki Kimura; Akihiko Takeuchi; Shinji Miwa; Kentaro Igarashi; Takashi Kato; Yu Aoki; Takashi Higuchi; Mayumi Hirose; Robert M Hoffman; Toshinari Minamoto; Hiroyuki Tsuchiya
Journal:  Oncotarget       Date:  2016-11-22

Review 7.  Glycogen Synthase Kinase 3β in Cancer Biology and Treatment.

Authors:  Takahiro Domoto; Masahiro Uehara; Dilireba Bolidong; Toshinari Minamoto
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

8.  β-Catenin Does Not Confer Tumorigenicity When Introduced into Partially Transformed Human Mesenchymal Stem Cells.

Authors:  Sajida Piperdi; Lukas Austin-Page; David Geller; Manpreet Ahluwalia; Sarah Gorlick; Jonathan Gill; Amy Park; Wendong Zhang; Nan Li; So Hak Chung; Richard Gorlick
Journal:  Sarcoma       Date:  2012-10-18

9.  The prognostic significance of CD44V6, CDH11, and β-catenin expression in patients with osteosarcoma.

Authors:  Zhouming Deng; Guangfeng Niu; Lin Cai; Renxiong Wei; Xiaolei Zhao
Journal:  Biomed Res Int       Date:  2013-07-18       Impact factor: 3.411

10.  The genetic basis for inactivation of Wnt pathway in human osteosarcoma.

Authors:  Xiaoling Du; Jilong Yang; Da Yang; Wei Tian; Ze Zhu
Journal:  BMC Cancer       Date:  2014-06-18       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.